fashion -WSS

fashion

author：Wikipedia 2025-10-02 08:24:20 - browse：65

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Paying for Covid pills will soon shift to insurers

hotspot

WSS

Readout Newsletter: XBI biotech index, Akero Therapeutics

Telehealth options flood the market as retailers push virtual care

Meta's Zuckerberg and Chan on track to put $50 billion into science

Prosthetic arm enables patients to feel the objects they grip

Scientists successfully use ultrasound imaging to map brain activity

Heat waves linked to early deliveries, preterm births in new study

leisure time

fashion

Wikipedia

Cancer drug shortages should be causing more outrage

Biden's order seeks to regulate AI risk without stifling innovation

Medicare details structure of new drug price negotiation program

Biden's order seeks to regulate AI risk without stifling innovation

Malaria cases in Florida and Texas: Here’s what you need to know

Emergency medicine has repudiated 'excited delirium.' Now what?

Malaria cases in Florida and Texas: Here’s what you need to know

Lab trade group sues FDA to halt regulation of lab

Novavax promises a turnaround & Lilly roils the obesity market

Medtronic CEO on promising devices for diabetes, hypertension

hotspot

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Traditional Chinese medicine benefits explored in new JAMA study

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Biohaven protein

Dark money group runs ads on China biotech bill

hotspot

hotspot

focus

hotspot